tradingkey.logo

GlucoTrack Inc

GCTK
View Detailed Chart

6.230USD

0.0000.00%
Close 08/01, 16:00ETQuotes delayed by 15 min
2.66MMarket Cap
LossP/E TTM

GlucoTrack Inc

6.230

0.0000.00%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.30%

5 Days

-16.04%

1 Month

-5.89%

6 Months

+446.49%

Year to Date

-16.49%

1 Year

-77.10%

View Detailed Chart

Agency Rating

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(6)
Neutral(3)
Buy(2)
Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.470
Neutral
RSI(14)
52.164
Neutral
STOCH(KDJ)(9,3,3)
14.405
Oversold
ATR(14)
0.989
High Vlolatility
CCI(14)
-46.122
Neutral
Williams %R
75.862
Sell
TRIX(12,20)
1.558
Sell
StochRSI(14)
11.194
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
6.430
Sell
MA10
7.069
Sell
MA20
6.437
Sell
MA50
4.270
Buy
MA100
2.239
Buy
MA200
6.249
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Ticker SymbolGCTK
CompanyGlucoTrack Inc
CEOMr. Paul V. Goode, Ph.D.
Website
KeyAI